Biogen (BIIB) Income towards Parent Company (2009 - 2026)
Biogen (BIIB) recorded quarterly Income towards Parent Company of $319.5 million in Q1 2026, up 753.37% quarter-over-quarter from -$48.9 million in Q4 2025, and up 32.85% on a YoY basis from $240.5 million in Q1 2025.
Biogen (BIIB) Income towards Parent Company (2009 - 2026) Analysis & Trends
Biogen's Income towards Parent Company history runs 18 years deep, the most recent figure standing at $319.5 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 32.85% year-over-year to $319.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 7.26% YoY), while the FY2025 annual figure was $1.3 billion, down 20.79% from the prior year.
- Income towards Parent Company was $319.5 million for Q1 2026 at Biogen, up from -$48.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $1.1 billion in Q3 2022 to a low of -$64.2 million in Q3 2023.
- Historically, Income towards Parent Company has averaged $437.3 million across 5 years, with a median of $393.4 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company surged 948.37% in 2022, then tumbled 118.34% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at $559.0 million in 2022, then plunged by 55.47% to $248.9 million in 2023, then advanced by 7.15% to $266.7 million in 2024, then sank by 118.34% to -$48.9 million in 2025, then surged by 753.37% to $319.5 million in 2026.
- The last three Income towards Parent Company figures came in at $319.5 million (Q1 2026), -$48.9 million (Q4 2025), and $466.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 319.50 Mn |
| Dec 31, 2025 | -48.90 Mn |
| Sep 30, 2025 | 466.50 Mn |
| Jun 30, 2025 | 634.80 Mn |
| Mar 31, 2025 | 240.50 Mn |
| Dec 31, 2024 | 266.70 Mn |
| Sep 30, 2024 | 388.50 Mn |
| Jun 30, 2024 | 583.60 Mn |
| Mar 31, 2024 | 393.40 Mn |
| Dec 31, 2023 | 248.90 Mn |
| Sep 30, 2023 | -64.20 Mn |
| Jun 30, 2023 | 599.70 Mn |
| Mar 31, 2023 | 397.20 Mn |
| Dec 31, 2022 | 559.00 Mn |
| Sep 30, 2022 | 1.14 Bn |
| Jun 30, 2022 | 1.06 Bn |
| Mar 31, 2022 | 243.40 Mn |
| Dec 31, 2021 | -101.70 Mn |
| Sep 30, 2021 | -134.80 Mn |
| Jun 30, 2021 | 528.30 Mn |